secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioXcel Therapeutics, Inc. (BTAI)
CIK:        0001720893
Form:       8-K
Filed at:   2026-02-12T23:59:59+00:00
Accession:  0001104659-26-013840
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

BioXcel updates IGALMI at-home opportunity: up to 86M annual episodes, sNDA pending
--------------------------------------------------------------------------------

- Updated market assessment for IGALMI at-home use identifies up to 86M addressable annual episodes, up from prior 57-77M estimate.
- sNDA seeking FDA approval for at-home use submitted last month; assessment based on SERENITY At-Home study and market research.
- Prescribers project using IGALMI in ~70% of schizophrenia/bipolar disorder patients; patients expect use in ~80% of agitation episodes.
- Claims data: ~2.3M treated patients experience frequent acute agitation at home; up to 1.8M may be eligible for IGALMI.
- Payers indicated expectations for broad formulary coverage with standard adjudication controls; prescribers report moderate-high unmet need.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1720893/000110465926013840/0001104659-26-013840-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1720893/000110465926013840/tm266150d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-013840

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer